AAA today announced that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.” This approval allows for the marketing of lutetium (177Lu) oxodotreotide (Lutathera®) in all 28 European Union member states, as well as Iceland, Norway and Liechtenstein.